Morpholine-spirocyclic piperidine amides as modulators of ion channels
3 Assignments
0 Petitions
Accused Products
Abstract
The invention relates to morpholine spirocyclic piperidine amide compounds useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
-
Citations
79 Claims
-
1. A compound of formula I:
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79)
-
2. The compound of claim 1, wherein R1 is optionally substituted aryl, heteroaryl, C1-C6 alkyl, C1-C6 fluoroalkyl, a straight chain, branched, or cyclic-(C3-C8)—
- R9 wherein up to two CH2 units may be replaced with O, CO, S, SO, SO2, N, or NR8.
-
3. The compound of claim 1, wherein R1 is F, or optionally substituted phenyl, pyridyl, oxazole, thiazole, pyrazole, oxadiazole, CH2OCH3, CH2F, CH2OCH(CH3)2, CH2OCHF2, CH3, CH2CH3, CH2OH, C(CH3)2OH, CH2CH2OH, CH2OCH2CH3, CH(CH2)2,
-
4. The compound of claim 1, wherein R2 is H, C1-C6 alkyl, C1-C6 fluoroalkyl, CF3, cycloalkyl, aryl, heterocycloalkyl, heteroaryl, or a straight chain, branched, or cyclic-(C3-C8)—
- R9 wherein up to two CH2 units may be replaced with O, CO, S, SO, SO2, N, or NR8.
-
5. The compound of claim 1, wherein R2 is H, CH2CHF2, CH2CF3, CH(CH3)CH2F, CH2CH(CH3)2, CH3, CH2CH3, tBu, CH2CN, CH(CH3)2, CH2C(CH3)2OH, CH2CH2CH(CH3)2, CH2CH2OH, C(O)CH2CH3, C(O)CH(CH3)2, CH(CH3)CH2F, CH2CH(CH3)2, CH(CH2CH3)2, CH2C(CH3)2OH, CH2CH2CH(CH3)2, CH2CH2OH, C(O)CH3, C(O)CH2CH3, C(O)CH(CH3)2, CH2CF2CH3, CH2CCCH3, CH2C(O)tBu, CH2CH2OCH3, CH2OCH3, CH2C(O)CH3, CH2C(O)OCH3, CH2CH2OCH2CH2CH3, CH2CCCH2CH3, CH2CH2OCH2CH3, CH2CH2SCH3, CH2CH2CH2OCH3, CH2CH(CH2CH3)2, n-butyl, n-propyl,
-
6. The compound of claim 1, wherein n is 0, 1, 2, or 3.
-
7. The compound of claim 1, wherein n is 1 or 2.
-
8. The compound of claim 1, wherein n is 1.
-
9. The compound of claim 1, wherein o is 0 or 1.
-
10. The compound of claim 1, wherein o is 0.
-
11. The compound of claim 1, wherein A is
-
12. The compound of claim 11, wherein R4 is H, C1-C6 alkyl, halo, or OCHF2.
-
13. The compound of claim 11, wherein R4 is H, F, CH3, or OCHF2.
-
14. The compound of claim 11, wherein R5 is H, C1-C6 alkyl, C1-C6 alkoxy, halo, CF3, CN, or a straight chain, branched, or cyclic-(C3-C8)—
- R9 wherein up to three CH2 units may be replaced with O, CO, S, SO, SO2, N, or NR8.
-
15. The compound of claim 11, wherein R5 is H, CH3, OCH3, OCH2CH3, OCH(CH3)2, F, Cl, CF3, CN, or CH2OH.
-
16. The compound of claim 11, wherein R6 is H, C1-C6 alkyl, C1-C6 alkoxy, SO2R8, SO2N(R8)2, R9, or a straight chain, branched, or cyclic (C3-C8)—
- R9, wherein up to three CH2 units may be replaced with O, S, SO, SO2, N, or NR8.
-
17. The compound of claim 11, wherein R6 is H, CH2OH, OCH3, OCH2CH3, OCH2CH2CH3, OCH2CH2CH(CH3)2, OtBu, tBu, OCH(CH3)2, OCH2C(CH3)2OCH3, CH(OH)CH(CH3)2, C(OH)(CH2CH3)2, OCH2C(CH3)2OH, C(CH3)2OH, OCH2CH2OCH3, OCH2CH2OH, OCH2CH2CH2OH, CCCH2OCH3, SO2CH3, SO2CH2CH(CH3)2, SO2CH(CH3)2, SO2CH2CH3, SO2C(CH3)3, CON(CH2CH3)2, C(CH3)2CO2CH3,
-
18. The compound of claim 11, wherein
-
19. The compound of claim 1, wherein A is heteroaryl or heterocyclic.
-
20. The compound of claim 19, wherein A is a monocyclic heteroaryl comprising 1 to 3 heteroatoms, wherein said heteroatoms are independently N, O, or S.
-
21. The compound of claim 19, wherein A is a bicyclic heteroaryl comprising from 1 to 3 heteoratoms, wherein said heteroatoms are independently N, O, or S.
-
22. The compound of claim 19, wherein A is
-
23. The compound of claim 22, wherein R4 is H or C1-C6 alkyl.
-
24. The compound of claim 22, wherein R4 is H.
-
25. The compound of claim 22, wherein R5 is H, C1-C6 alkyl, or C1-C6 alkoxy.
-
26. The compound of claim 22, wherein R5 is H, CH3, or OCH3.
-
27. The compound of claim 22, wherein R6 is H, CN, C1-C6 alkoxy, or CF3.
-
28. The compound of claim 22, wherein R6 is H, CN, OCH3, or CF3.
-
29. The compound of claim 22, wherein A is:
-
30. The compound of claim 1, wherein the compound has formula IA:
-
31. The compound of claim 30, wherein R2 is C1-C6 alkyl, C1-C6 fluoroalkyl, cycloalkyl, aryl, heterocycloalkyl, heteroaryl, or a straight chain, branched, or cyclic-(C3-C8)—
- R9 wherein up to two CH2 units may be replaced with O, CO, S, SO, SO2, N, CF2, or NR8.
-
32. The compound of claim 30, wherein R2 is CH3, CH2CH3, CH(CH3)2, CH2CH(CH3)2, CH2CHF2, CH2CF3, CH(CH3)CH2F, CH2CN, CH2CH2OH, CH2C(CH3)2OH, COCH2CH3, or COCH(CH3)2.
-
33. The compound of claim 30, wherein R5 is H, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 fluroroalkyl, halo, or a straight chain, branched, or cyclic (C3-C8)—
- R9 wherein up to three CH2 units may be replaced with O, CO, S, SO, SO2, N, CF2, or NR8.
-
34. The compound of claim 30, wherein R5 is H, CH3, OCH3, OCH2CH3, CF3, Cl, F, or CH2OH.
-
35. The compound of claim 30, wherein R6 is H, C1-C6 alkoxy, or a straight chain, branched, or cyclic-(C3-C8)—
- R9 wherein up to three CH2 units may be replaced with O, CO, S, SO, SO2, N, CF2, or NR8.
-
36. The compound of claim 30, wherein R6 is H, CH2OH, OCH2CH3, OtBu, OCH(CH3)2, OCH2C(CH3)2OCH3, CH(OH)CH(CH3)2, OCH2C(CH3)2OH, C(CH3)2OH, OCH2CH2OCH3, OCH2CH2OH, OCH2CH2CH2OH, CCCH2OCH3, SO2CH3, SO2CH2CH(CH3)2, SO2CH(CH3)2, SO2CH2CH3, SO2C(CH3)3, CON(CH2CH3)2, C(CH3)2CO2CH3,
-
37. The compound of claim 30, wherein R7 is halo.
-
38. The compound of claim 30, wherein R7 is F.
-
39. The compound of claim 30, wherein the
-
40. The compound of claim 30, wherein the compound has formula IB:
-
41. The compound of claim 40, wherein R2 is C1-C6 alkyl, C1-C6 fluoroalkyl, or a straight chain, branched, or cyclic-(C3-C8)—
- R9 wherein up to two CH2 units may be replaced with O, CO, S, SO, SO2, N, CF2, or NR8.
-
42. The compound of claim 40, wherein R2 is CH3, CH2CH3, CH(CH3)2, CH2CH(CH3)2, CH2CHF2, CH2CF3, CH(CH3)CH2F, CH2CN, CH2CH2OH, CH2C(CH3)2OH, COCH2CH3, or COCH(CH3)2.
-
43. The compound of claim 40, wherein R5 is H, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 fluroroalkyl, halo, or a straight chain, branched, or cyclic (C3-C8)—
- R9 wherein up to three CH2 units may be replaced with O, CO, S, SO, SO2, N, CF2, or NR8.
-
44. The compound of claim 40, wherein R5 is H, CH3, OCH3, OCH2CH3, CF3, Cl, F, or CH2OH.
-
45. The compound of claim 40, wherein R6 is H, C1-C6 alkoxy, or a straight chain, branched, or cyclic-(C3-C8)—
- R9 wherein up to three CH2 units may be replaced with O, CO, S, SO, SO2, N, CF2, or NR8.
-
46. The compound of claim 40, wherein R6 is H, CH2OH, OCH2CH3, OtBu, OCH(CH3)2, OCH2C(CH3)2OCH3, CH(OH)CH(CH3)2, OCH2C(CH3)2OH, C(CH3)2OH, OCH2CH2OCH3, OCH2CH2OH, OCH2CH2CH2OH, CCCH2OCH3, SO2CH3, SO2CH2CH(CH3)2, SO2CH(CH3)2, SO2CH2CH3, SO2C(CH3)3, CON(CH2CH3)2, C(CH3)2CO2CH3,
-
47. The compound of claim 40, wherein R7 is halo.
-
48. The compound of claim 40, wherein R7 is F.
-
49. The compound of claim 40, wherein the
-
50. The compound of claim 1, wherein the compound has formula IC:
-
51. The compound of claim 50, wherein the Het ring is an optionally substituted thiazole, pyridine, pyrazole, oxazole, or oxadiazole.
-
52. The compound of claim 50, wherein p is 0 or 1.
-
53. The compound of claim 50, wherein, R7 is C1-C6 alkyl.
-
54. The compound of claim 50, wherein, R7 is CH3, CH2CH3, CH(CH3)2, or tBu.
-
55. The compound of claim 50, wherein the Het ring is
-
56. The compound of claim 50, wherein R2 is C1-C6 alkyl or a straight chain, branched, or cyclic-(C3-C8)—
- R9 wherein up to two CH2 units may be replaced with O, CO, S, SO, SO2, N, CF2, or NR8.
-
57. The compound of claim 50, wherein R2 is CH2CH3, tBu, CH2CHF2, CH2CF3, or
-
58. The compound of claim 50, wherein R5 is H, C1-C6 alkyl, C1-C6 alkoxy, or halo.
-
59. The compound of claim 50, wherein R5 is H, CH3, OCH3, F, or Cl.
-
60. The compound of claim 50, wherein R6 is H, C1-C6 alkoxy, or a straight chain, branched, or cyclic-(C3-C8)—
- R9 wherein up to three CH2 units may be replaced with O, CO, S, SO, SO2, N, CF2, or NR8.
-
61. The compound of claim 50, wherein R6 is OCH(CH3)2, C(CH3)2OH, OCH2CH2OH, OCH2CH2CH2OH,
-
62. The compound of claim 1, wherein the compound has formula ID:
-
63. The compound of claim 62, wherein the Het ring is an optionally substituted thiazole, pyridine, pyrazole, oxazole, or oxadiazole.
-
64. The compound of claim 62, wherein p is 0 or 1.
-
65. The compound of claim 62, wherein R7 is C1-C6 alkyl.
-
66. The compound of claim 62, wherein R7 is CH3, CH2CH3, CH(CH3)2, or tBu.
-
67. The compound of claim 62, wherein the Het ring is
-
68. The compound of claim 62, wherein R2 is C1-C6 alkyl or a straight chain, branched, or cyclic-(C3-C8)—
- R9 wherein up to two CH2 units may be replaced with O, CO, S, SO, SO2, N, CF2, or NR8.
-
69. The compound of claim 62, wherein R2 is CH2CH3, tBu, CH2CHF2, CH2CF3, or
-
70. The compound of claim 62, wherein R5 is H, C1-C6 alkyl, C1-C6 alkoxy, or halo.
-
71. The compound of claim 62, wherein R5 is H, CH3, OCH3, F, or Cl.
-
72. The compound of claim 62, wherein R6 is H, C1-C6 alkoxy, or a straight chain, branched, or cyclic-(C3-C8)—
- R9 wherein up to three CH2 units may be replaced with O, CO, S, SO, SO2, N, CF2, or NR8.
-
73. The compound of claim 62, wherein R6 is OCH(CH3)2, C(CH3)2OH, OCH2CH2OH, OCH2CH2CH2OH,
-
74. The compound of claim 1, wherein the compound is selected from the following table:
-
75. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
-
76. A method of inhibiting a voltage-gated sodium ion channel in:
-
a patient;
ora biological sample; comprising administering to the patient, or contacting the biological sample, with the compound or composition of claim 1.
-
-
77. The method of claim 76, wherein the voltage-gated sodium ion channel is NaV 1.7.
-
78. A method of treating or lessening the severity in a subject of acute, chronic, neuropathic, or inflammatory pain, arthritis, migraine, cluster headaches, trigeminal neuralgia, herpatic neuralgia, general neuralgias, epilepsy or epilepsy conditions, neurodegenerative disorders, psychiatric disorders, anxiety, depression, dipolar disorder, myotonia, arrhythmia, movement disorders, neuroendocrine disorders, ataxia, multiple sclerosis, irritable bowel syndrome, incontinence, visceral pain, osteoarthritis pain, postherpetic neuralgia, diabetic neuropathy, radicular pain, sciatica, back pain, head or neck pain, severe or intractable pain, nociceptive pain, breakthrough pain, postsurgical pain, cancer pain, stroke, cerebral ischemia, traumatic brain injury, amyotrophic lateral sclerosis, stress- or exercise induced angina, palpitations, hypertension, migraine, or abormal gastro-intestinal motility, comprising administering an effective amount of a compound of claim 1.
-
79. The method of claim 78, wherein said method is used for treating or lessening the severity of femur cancer pain;
- non-malignant chronic bone pain;
rheumatoid arthritis;
osteoarthritis;
spinal stenosis;
neuropathic low back pain;
neuropathic low back pain;
myofascial pain syndrome;
fibromyalgia;
temporomandibular joint pain;
chronic visceral pain, abdominal pain;
pancreatic;
IBS pain;
chronic and acute headache pain;
migraine;
tension headache, including, cluster headaches;
chronic and acute neuropathic pain, post-herpatic neuralgia;
diabetic neuropathy;
HIV-associated neuropathy;
trigeminal neuralgia;
Charcot-Marie Tooth neuropathy;
hereditary sensory neuropathies;
peripheral nerve injury;
painful neuromas;
ectopic proximal and distal discharges;
radiculopathy;
chemotherapy induced neuropathic pain;
radiotherapy-induced neuropathic pain;
post-mastectomy pain;
central pain;
spinal cord injury pain;
post-stroke pain;
thalamic pain;
complex regional pain syndrome;
phantom pain;
intractable pain;
acute pain, acute post-operative pain;
acute musculoskeletal pain;
joint pain;
mechanical low back pain;
neck pain;
tendonitis;
injury/exercise pain;
acute visceral pain, abdominal pain;
pyelonephritis;
appendicitis;
cholecystitis;
intestinal obstruction;
hernias;
chest pain, cardiac pain;
pelvic pain, renal colic pain, acute obstetric pain, labor pain;
cesarean section pain;
acute inflammatory, burn and trauma pain;
acute intermittent pain, endometriosis;
acute herpes zoster pain;
sickle cell anemia;
acute pancreatitis;
breakthrough pain;
orofacial pain including sinusitis pain, dental pain;
multiple sclerosis (MS) pain;
pain in depression;
leprosy pain;
Behcet'"'"'s disease pain;
adiposis dolorosa;
phlebitic pain;
Guillain-Barre pain;
painful legs and moving toes;
Haglund syndrome;
erythromelalgia pain;
Fabry'"'"'s disease pain;
bladder and urogenital disease, including, urinary incontinence;
hyperactivity bladder;
painful bladder syndrome;
interstitial cyctitis (IC);
prostatitis;
complex regional pain syndrome (CRPS), type I and type II;
widespread pain, paroxysmal extreme pain, pruritic, tinnitis, or angina-induced pain.
- non-malignant chronic bone pain;
-
2. The compound of claim 1, wherein R1 is optionally substituted aryl, heteroaryl, C1-C6 alkyl, C1-C6 fluoroalkyl, a straight chain, branched, or cyclic-(C3-C8)—
Specification
- Resources
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeVertex Pharmaceuticals Incorporated
-
Original AssigneeVertex Pharmaceuticals Incorporated
-
InventorsHadida-Ruah, Sara Sabina, Binch, Hayley Marie, DeNinno, Michael Paul, Fanning, Lev Tyler Dewey, Frieman, Bryan A., Grootenhuis, Peter Diederik Jan, Hilgraf, Nicole, Joshi, Pramod, Kallel, Edward Adam, Miller, Mark Thomas, Pontillo, Joseph, Silina, Alina, Sheth, Urvi Jagdishbhai, Hurley, Dennis James, Arumugam, Vijayalaksmi
-
Primary Examiner(s)Habte, Kahsay
-
Application NumberUS13/418,737Publication NumberTime in Patent Office910 DaysField of Search544/71, 514/232.2, 514/235.8, 514/235.5US Class Current514/232.2CPC Class CodesA61P 1/00 Drugs for disorders of the ...A61P 1/02 Stomatological preparations...A61P 1/04 for ulcers, gastritis or re...A61P 1/16 for liver or gallbladder di...A61P 1/18 for pancreatic disorders, e...A61P 11/02 Nasal agents, e.g. deconges...A61P 13/02 of urine or of the urinary ...A61P 13/08 of the prostateA61P 13/10 of the bladderA61P 13/12 of the kidneysA61P 17/04 AntipruriticsA61P 19/00 Drugs for skeletal disordersA61P 19/02 for joint disorders, e.g. a...A61P 25/00 Drugs for disorders of the ...A61P 25/06 Antimigraine agentsA61P 25/08 Antiepileptics; Anticonvuls...A61P 25/14 for treating abnormal movem...A61P 25/18 Antipsychotics, i.e. neurol...A61P 25/22 AnxiolyticsA61P 25/24 AntidepressantsA61P 25/28 : for treating neurodegenerat...A61P 29/00 : Non-central analgesic, anti...A61P 3/10 : for hyperglycaemia, e.g. an...A61P 43/00 : Drugs for specific purposes...A61P 5/00 : Drugs for disorders of the ...A61P 7/06 : AntianaemicsA61P 9/00 : Drugs for disorders of the ...A61P 9/06 : AntiarrhythmicsA61P 9/12 : AntihypertensivesC07D 498/10 : Spiro-condensed systems